Back to search results

Bladder Bank: Collecting Samples for Bladder Cancer Detection

This study, called the "Bladder Bank," is collecting blood and urine samples from people with bladder cancer. The goal is to create a collection of samples that researchers can use to develop new, non-invasive tests for finding bladder cancer early. This study is observational, meaning you won't receive any new treatments; instead, researchers will collect samples and review your medical records. To join, you must be at least 18 years old and have already had an office evaluation for hematuria (blood in urine), which includes tests like a CT scan, ultrasound, or cystoscopy (a procedure to look inside the bladder). The study aims to enroll 1500 participants. The current recruitment status is unclear.

Study design
This is an observational study aiming to enroll 1500 participants. It is not a treatment study.
What's involved
You would provide blood and urine samples, and your medical records would be reviewed.
Compensation
Not stated in the trial record.
Follow-up
Samples are collected at Baseline (at enrollment).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06109857

Bladder Bank (a Prospective Banking Study)

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~1,500 participants
Updated 2026-03-16 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Blood sample to support the development of non-invasive tests for early detection of bladder cancer
Measured over Baseline (at enrollment)
+1 more outcome measured

Conditions

Bladder Carcinoma

Explore related trials

Bladder Carcinoma

NCT06109857

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • John B. Kisiel, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \> 18 years
Patient has undergone office-based evaluation for hematuria \[computed tomography (CT), ultrasound, cystoscopy\]

Exclusion

Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible)
Patient has recurrent muscle invasive bladder cancer
Patient has ever been previously diagnosed with UTUC (upper tract urothelial carcinoma) prior to bladder resection
Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection
Patient has had any prior radiation therapy to the target lesion prior to current collection
Patient has had a biopsy to the target organ and/or lesion within 3 days before collection
Patient has undergone cystectomy or cystoprostatectomy
Patient has transurethral instrumentation (placement of urinary catheter) within 7 days prior to urine collection
Patient has had a urinary tract infection within 14 days prior to urine collection
Patient has chronic indwelling urinary catheter

What this trial measures

  • Blood sample to support the development of non-invasive tests for early detection of bladder cancerBaseline (at enrollment)

    At study enrollment for subjects, 60 ml (4 tablespoons) of blood will be drawn from all participants and processed according to standardized study biospecimen protocol. All samples will be stored for future analysis in Molecular Cancer Diagnostic Laboratory at Mayo Clinic.

  • Urine sample to support the development of non-invasive tests for early detection of bladder cancerBaseline (at enrollment)

    At study enrollment for subjects, up to 20mL of urine will be collected from the same or unique case patients identified for blood collection. All samples will be stored for future analysis in Molecular Cancer Diagnostic Laboratory at Mayo Clinic.